Delisting risk
Protagenic Therapeutics (PTIX)
Developing PT00114 for stress-related neuropsychiatric disorders.
$1.15
At close−0.04 (−3.36%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions4 holders · as of Mar 31, 2026 | 3.70% | 66.9K shares | |
| Insiders2 holders · as of Aug 24, 2026 | 4.96% | 89.8K shares | |
| Otherremainder | 91.34% | 1.65M shares |
1.81M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
4 holders · 66.9K shares · 1 new position · 1 increased · 1 reduced · 8 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| DRW Securities, LLC | 41.8K | 2.31% | −1.1K | May 13, 2026 |
| FNY Investment Advisers, LLC | 25.0K | 1.38% | 0 | Apr 15, 2026 |
| Corecap Advisors, LLC | 100 | 0.01% | +100new | Apr 7, 2026 |
| United Financial Planning Group LLC | 17 | 0.00% | 0 | May 8, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 21, 2026 | Garo H. Armendirector, officer: EXEC. CHAIR & PRINCIPAL OFF | Purchase | 20,000 | $0.6500 | 73,533 |
| Aug 20, 2026 | Garo H. Armendirector, officer: EXEC. CHAIR & PRINCIPAL OFF | Purchase | 16,634 | $0.5898 | 53,533 |
| Aug 19, 2026 | Garo H. Armendirector, officer: EXEC. CHAIR & PRINCIPAL OFF | Purchase | 2,700 | $0.3500 | 36,899 |
| Aug 11, 2026 | Garo H. Armendirector, officer: EXEC. CHAIR & PRINCIPAL OFF | Purchase | 2,220 | $0.3200 | 34,199 |
| Aug 6, 2026 | Garo H. Armendirector, officer: EXEC. CHAIR & PRINCIPAL OFF | Purchase | 685 | $0.2200 | 31,979 |
| Aug 5, 2026 | Garo H. Armendirector, officer: EXEC. CHAIR & PRINCIPAL OFF | Purchase | 5,000 | $0.2588 | 31,294 |
| Jul 30, 2026 | Garo H. Armendirector, officer: EXEC. CHAIR & PRINCIPAL OFF. | Purchase | 26,291 | $0.1828 | 26,291 |
CongressHouse and Senate disclosures
Not reported.
